Regulatory and Analytical Science of Biosimilars: A Pharmaceutical Chemistry Perspective

The development and approval of biosimilars represent a significant advancement in pharmaceutical science, offering cost-effective therapeutic alternatives to originator biologics. From a pharmaceutical chemistry perspective, the regulatory and analytical evaluation of biosimilars demands a rigorous, multidisciplinary approach to ensure comparable quality, safety, and efficacy. This abstract explores the critical scientific and regulatory frameworks that govern biosimilar development, emphasizing the role of advanced analytical techniques in structural and functional characterization. It discusses key regulatory guidelines from global authorities such as the FDA and EMA, highlighting the stepwise approach in demonstrating bio similarity through quality attributes, non-clinical, and clinical studies. Analytical science plays a central role in deciphering complex molecular structures, glycosylation patterns, and post-translational modifications, using techniques such as mass spectrometry, chromatography, and bioassays. This perspective also addresses the challenges in establishing interchangeability, immunogenicity assessment, and manufacturing consistency. By integrating regulatory requirements with cutting-edge analytical methodologies, pharmaceutical chemists contribute crucially to the reliable development and approval of biosimilars, ensuring therapeutic equivalence and patient safety.